Those are symptoms of LUTS/BPH.
The daily use of a PDE5i can definitely improve symptoms of LUTS/BPH.
It is common for many to experience side-effect (varying degrees) when first starting daily tadalafil.
Just tough it out as they will eventually fade and to what degree will depend on the dose used/individual.
There are many other beneficial effects when it comes to daily use of aPDE5i.
Regarding your hrt protocol(dose T/injection frequency) post your labs with the reference ranges/assays used for TT/FT/e2.
What is your SHBG?
Your original protocol of 200 mg T/week is a whopping dose of T to be started on as it would result in very high TT/FT/e2 levels let alone drive up your RBCs/hemoglobin/hematocrit.
Purpose: This study aimed to compare the efficacy and safety of combination therapy consisting of a-blockers and different phosphodiesterase type 5 inhibitors for lower urinary tract symptoms (LUTS) by performing a network meta-analysis. Method: Relevant articles were retrieved from the...
www.excelmale.com
Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) are prevalent conditions that have negative impacts on quality of life and self-confidence.[1,2] The prevalence of LUTS in men aged over 50 years old has been reported to be more than 50%.[3] Based on the pathophysiological relationships between BPH-LUTS and ED, several studies have confirmed that both diseases often coexist and have a growing prevalence with age.[4,5]
6. Conclusions
In conclusion, combination therapy with a-blockers and PDE5Is was significantly more effective than a-blocker monotherapy at improving LUST. Among the combinations, vardenafil (10mg) combined with a-blockers, sildenafil (25mg) combined with a-blockers, and tadalafil (20mg) combined with a-blockers appear to be better choices than monotherapies with either a-blockers or PDE5Is and other combination therapies of a-blockers plus PDE5Is in terms of efficacy. However, our present results need to be verified with more high-quality studies with comprehensive data.
Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED A. Sebastianelli & P. Spatafora & S. Morselli & L. Vignozzi & S. Serni & K. T. McVary & S. Kaplan & S. Gravas & C. Chapple & Mauro Gacci Abstract Purpose of Review Aim of our systematic review is to...
www.excelmale.com
Conclusions
In conclusion, daily tadalafil, in particular at a dosage of 5 mg, is effective for the treatments of LUTS/BPH and ED. All the available evidence shows that the occurrence of TEAEs is low and most of the patients are “satisfied” by this treatment. Combination therapy of tadalafil 5 mg and tamsulosin 0.4 mg allows a further improvement of urinary symptoms and ED, against a higher rate of TAEs. Discontinuation of tamsulosin or tadalafil, after combination therapy, seems to allow preservation of the results obtained for LUTS relief. However, tadalafil only is able to retain ED improvement.
Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects ABSTRACT Introduction: Benign prostate hyperplasia (BPH) is one of the most prevalent diseases in aging men. It may adversely affect...
www.excelmale.com
8. Expert opinion
First-line therapy for BPH/LUTS syndrome is represented by α1-adrenoreceptor blockers. The adverse-event profile of these drugs depends on the affinity rather than selectivity for the α1Aadrenoceptor. Hence, the probability of ejaculatory dysfunctions is highest with silodosin than with other drugs with lower affinity for this receptor subtype (tamsulosin, alfuzosin, doxazosin, and terazosin). However, classifying these patients by age (older vs. younger) and sexual activity (present or not), the use of PDE5is should be considered even if this is more expensive especially when BPH/LUTS coexists with ED. Indeed, due to the benefits of erection, PDE5i represents the most advantageous class of drugs for the treatment of LUTS-BPH in patients with ED. Interestingly, the remarkable effects of daily PDE5is on body composition and endothelial function other than sexual improvements are reported [121] and suggest a pleiotropic beneficial effect of these drugs. LUTS-BPH often associates with metabolic syndrome, although the exact mechanism has not been clarified yet. Molecular studies address insulin as a role in prostatic hyperplasia and inflammation [122].
www.excelmale.com
www.excelmale.com
www.excelmale.com
In conclusion, taking tadalafil 5 mg once daily reduced PMD symptom severity and PMD volume in men with PMD and other LUTS more effectively than placebo. The present results also show that tadalafil does not induce serious TEAEs. These results suggest that taking tadalafil 5 mg once daily may be an effective and well-tolerated PMD treatment, and suggest that PDE-5 inhibitors have a potential role in treating PMD.
www.excelmale.com
Expert opinion: Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility.
Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH.
Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than α1- adrenoceptors and should be used as the first option. Tadalafil is a safe and tolerable therapy and unlike α1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, tadalafil improves sexual function.
8. Conclusion
Tadalafil represents a well-tolerated and effective treatment option in men with LUTS-BPH with or without ED. As LUTS-BPH and ED can appear concomitantly in aging men, a drug that improves the signs and symptoms of both conditions is of therapeutic relevance.
www.excelmale.com
www.excelmale.com
Conclusions
The treatment with tadalafil for 12 months significantly relieved storage and voiding functions, along with LUTS, in patients diagnosed with LUTS/BPH. Monitoring the parameters of LUT function, such as bladder capacity, DO, Qmax, and BOOI, revealed that beneficial effects of tadalafil treatment observed at 3 months continued to improve until 12 months.